Which company produces avatrombopag (Avatrombopag, Sucoxin)?

Avatrombopag/Avatrombopag is a new thrombopoietin receptor agonist, mainly used to treat thrombocytopenia in patients with chronic liver disease. The drug works by stimulating the production of platelets in the bone marrow, thereby effectively increasing patients' platelet levels and helping them successfully undergo necessary invasive treatments. Avatrombopag is approved in multiple countries and regions, including the United States, Europe, and China, and is manufactured and sold by different companies in different markets.

In Europe and the United States, avatrombopag is manufactured and sold by Sweden's Orphan Biovitrum AB (Sobi) under the product name Doptelet. The company develops and delivers highly specialized medicines that provide solutions for patients suffering from rare diseases. Sobi has strong market influence globally, especially in the field of hematology, and its product line covers a variety of therapeutic drugs for blood-related diseases. Avatrombopag, one of its key products, is in line with the company's mission to improve patients' quality of life.

In the Chinese market, avatrombopag is sold by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. under the trade name Su Kexin. Fosun Pharma is a comprehensive pharmaceutical company focused on the research, development and commercialization of innovative drugs, especially in the fields of biopharmaceuticals and medical devices, with significant competitive advantages. Fosun Pharma's strategic goal is to provide patients with safer and more effective treatment options and improve their overall health. Therefore, the introduction of avatrombopag not only enriches Fosun Pharma's product portfolio, but also provides a new treatment option for Chinese patients with chronic liver disease.

Overall, as the global understanding of chronic liver disease and its complications increases, avatrombopag serves as a targeted treatment that meets an urgent need in this specific patient group. By increasing platelet production, the drug not only helps patients successfully complete treatment, but also improves their quality of life, allowing them to return to their daily lives.

Reference materials:https://www.asahi-kasei.com/news/2023/e230524_2.html